A detailed history of Bessemer Group Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 137 shares of TGTX stock, worth $4,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares
137
Holding current value
$4,804
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.21 - $25.28 $2,357 - $3,463
137 New
137 $3,000
Q4 2017

Jan 30, 2018

SELL
$7.35 - $12.3 $10,312 - $17,256
-1,403 Closed
0 $0
Q3 2017

Nov 03, 2017

BUY
$10.0 - $12.7 $14,030 - $17,818
1,403
1,403 $17,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.09B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.